The Glycogen Synthase Kinase 3 Beta pipeline drugs market research report outlays comprehensive information on the Glycogen Synthase Kinase 3 Beta targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Glycogen Synthase Kinase 3 Beta pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

The report also covers products from therapy areas such as Central Nervous System, Oncology, Musculoskeletal Disorders, and Genetic Disorders which include the indications Alzheimer’s Disease, Unspecified Central Nervous System Disorders, Lung Cancer, Pancreatic Cancer, Sarcopenia, Myotonic Dystrophy, Duchenne Muscular Dystrophy, and Menkes Disease (Kinky Hair Disease). It also reviews key players involved in Glycogen Synthase Kinase 3 Beta targeted therapeutics development with respective active and dormant or discontinued products.

The Glycogen Synthase Kinase 3 Beta pipeline targets constitutes close to 26 molecules. Out of which, approximately 18 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Preclinical, and Discovery stages are 1, 3, 9, and 5 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 4, and 4 molecule.

Glycogen Synthase Kinase 3 Beta overview

Glycogen synthase kinase 3 beta also known as GSK3B is an enzyme encoded by the GSK3B. It constitutively activate protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules. It mediates the development of insulin resistance by regulating activation of transcription factors. It regulates protein synthesis by controlling the activity of initiation factor 2B (EIF2BE/EIF2B5) in the same manner as glycogen synthase. It plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex. It phosphorylates MACF1, inhibiting its binding to microtubules which is critical for its role in bulge stem cell migration and skin wound repair. It regulates the circadian clock via phosphorylation of the major clock components including ARNTL/BMAL1, CLOCK and PER2.

For a complete picture of Glycogen Synthase Kinase 3 Beta’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.